Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents

Type 2 diabetes mellitus (T2DM) is a recognised risk factor for several cardiovascular (CV) conditions including heart failure (HF). Findings that reflect CV risk associated with T2DM medications have led to regulatory requirement of conducting CV outcome trials (CVOTs) for new antidiabetes drugs. O...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Stefan D. Anker
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2019
Materias:	cardiovascular outcome trials dpp-4 inhibitors glp-1 receptor agonists heart failure sglt-2 inhibitors type 2 diabetes mellitus Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/dd839f2ab3bf4e1e9d6388f31d4cd802
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dd839f2ab3bf4e1e9d6388f31d4cd802
record_format	dspace
spelling	oai:doaj.org-article:dd839f2ab3bf4e1e9d6388f31d4cd8022021-11-14T09:00:22ZHeart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents2072-03512072-037810.14341/DM10374https://doaj.org/article/dd839f2ab3bf4e1e9d6388f31d4cd8022019-12-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/10374https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Type 2 diabetes mellitus (T2DM) is a recognised risk factor for several cardiovascular (CV) conditions including heart failure (HF). Findings that reflect CV risk associated with T2DM medications have led to regulatory requirement of conducting CV outcome trials (CVOTs) for new antidiabetes drugs. Over the years, several CVOTs using different glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors have reported neutral or improved CV risks or hospitalisation for HF. However, these studies included only a small proportion of the patients with baseline HF thus limiting the available evidence. Ongoing trials such as EMPEROR programme and DAPA-HF in large patient populations with chronic HF could potentially broaden the use of these drugs beyond their conventional therapeutic indication.Stefan D. AnkerEndocrinology Research Centrearticlecardiovascular outcome trialsdpp-4 inhibitorsglp-1 receptor agonistsheart failuresglt-2 inhibitorstype 2 diabetes mellitusNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 22, Iss 5, Pp 467-472 (2019)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	cardiovascular outcome trials dpp-4 inhibitors glp-1 receptor agonists heart failure sglt-2 inhibitors type 2 diabetes mellitus Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	cardiovascular outcome trials dpp-4 inhibitors glp-1 receptor agonists heart failure sglt-2 inhibitors type 2 diabetes mellitus Nutritional diseases. Deficiency diseases RC620-627 Stefan D. Anker Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
description	Type 2 diabetes mellitus (T2DM) is a recognised risk factor for several cardiovascular (CV) conditions including heart failure (HF). Findings that reflect CV risk associated with T2DM medications have led to regulatory requirement of conducting CV outcome trials (CVOTs) for new antidiabetes drugs. Over the years, several CVOTs using different glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors have reported neutral or improved CV risks or hospitalisation for HF. However, these studies included only a small proportion of the patients with baseline HF thus limiting the available evidence. Ongoing trials such as EMPEROR programme and DAPA-HF in large patient populations with chronic HF could potentially broaden the use of these drugs beyond their conventional therapeutic indication.
format	article
author	Stefan D. Anker
author_facet	Stefan D. Anker
author_sort	Stefan D. Anker
title	Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
title_short	Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
title_full	Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
title_fullStr	Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
title_full_unstemmed	Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
title_sort	heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
publisher	Endocrinology Research Centre
publishDate	2019
url	https://doaj.org/article/dd839f2ab3bf4e1e9d6388f31d4cd802
work_keys_str_mv	AT stefandanker heartfailureoutcomesinpatientswithtype2diabetesmellitusfindingsfromthecardiovascularoutcometrialsofantidiabetesagents
_version_	1718429495039361024

Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents

Ejemplares similares